Related Experiment Video
Updated: Feb 10, 2026

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Genetic and genomic approaches to the detection of heart transplant rejection
Evan P Kransdorf1, Jon A Kobashigawa2
1Cedars-Sinai Heart Institute, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
Insights
Heart transplant rejection remains a major threat. Gene-expression testing offers a noninvasive method for monitoring rejection, improving allograft survival and patient outcomes in heart transplantation.
Area of Science:
- Cardiology
- Immunology
- Transplant Science
Background:
- Cardiac allograft rejection remains a primary challenge post-heart transplantation.
- Endomyocardial biopsy is the standard for rejection monitoring but is invasive.
- Over 100,000 heart transplants have been performed globally since 1967.
Purpose of the Study:
- To review the pathological and clinical aspects of cardiac allograft rejection.
- To discuss the development and application of gene-expression testing for rejection detection.
- To explore future 'omic' approaches for rejection surveillance.
Main Methods:
- Review of literature on cardiac allograft rejection.
- Discussion of gene-expression profiling (e.g., AlloMap®) for noninvasive monitoring.
- Exploration of emerging 'omic' technologies.
Main Results:
- Gene-expression testing provides a noninvasive alternative to endomyocardial biopsy.
- This technology aids in the management and surveillance of heart transplant recipients.
- Emerging 'omic' methods show promise for future rejection detection.
Conclusions:
- Noninvasive gene-expression testing is crucial for managing heart transplant recipients.
- Continued innovation in 'omic' technologies will further enhance rejection detection.
- Improved rejection surveillance strategies are vital for long-term allograft survival.
Abstract:
Since Christiaan Barnard performed the first heart transplant in 1967, over 100,000 heart transplants have been performed worldwide. As was true then, rejection remains the major threat to the function and survival of the allograft. The development of the endomyocardial biopsy as a means to monitor for rejection has allowed heart transplantation to thrive as a therapy for patients with end-stage heart disease. The need for a noninvasive method of rejection surveillance led to the development of the first genetic test for allograft rejection, the AlloMap®. In this article, after presenting the pathological and clinical features of cardiac allograft rejection, the authors discuss the development and application of gene-expression testing for the detection of cardiac allograft rejection. We then explore emerging 'omic' approaches that will be the rejection detection methods of the future.
Related Concept Videos
Genomics
Genetics of Speciation
What is Genetic Engineering?
Genome Size and the Evolution of New Genes
Hypothesis: Accept or Fail to Reject?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
Quantifying and Rejecting Outliers: The Grubbs Test

